Details of the Drug Combination

General Information of Drug Combination (ID: DCBV8KL)

Drug Combination Name
Sildenafil Nintedanib
Indication
Disease Entry Status REF
Idiopathic Pulmonary Fibrosis Phase 3 [1]
Component Drugs Sildenafil   DM4YDAJ Nintedanib   DMMQ2OW
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Sildenafil
Disease Entry ICD 11 Status REF
Alveolar capillary dysplasia with misalignment of pulmonary veins N.A. Approved [2]
Erectile dysfunction HA01.1 Approved [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [4]
Respiratory failure CB41 Investigative [2]
Sildenafil Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
HUMAN phosphodiesterase type 5 (PDE5) TTRYFSB PDE5A_HUMAN Inhibitor [8]
------------------------------------------------------------------------------------
Sildenafil Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3 (GNB3) OTA6HYBA GBB3_HUMAN Increases Response [9]
Angiotensin-converting enzyme (ACE) OTDF1964 ACE_HUMAN Increases Response [10]
------------------------------------------------------------------------------------
Indication(s) of Nintedanib
Disease Entry ICD 11 Status REF
Idiopathic pulmonary fibrosis CB03.4 Approved [5]
Non-small-cell lung cancer 2C25.Y Approved [6]
Ovarian neoplasm N.A. Approved [6]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [7]

References

1 ClinicalTrials.gov (NCT02802345) Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment
2 Sildenafil FDA Label
3 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 206401.
4 ClinicalTrials.gov (NCT04304313) A Pilot Study of Sildenafil in COVID-19. U.S. National Institutes of Health.
5 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 205832
6 Nintedanib FDA Label
7 ClinicalTrials.gov (NCT04338802) Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19. U.S. National Institutes of Health.
8 Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus. J Virol. 2005 Feb;79(3):1966-9. doi: 10.1128/JVI.79.3.1966-1969.2005.
9 Sildenafil response is influenced by the G protein beta 3 subunit GNB3 C825T polymorphism: a pilot study. J Urol. 2003 Mar;169(3):1048-51. doi: 10.1097/01.ju.0000058369.72348.ba.
10 ACE gene I/D and NOS3 G894T polymorphisms and response to sildenafil in men with erectile dysfunction. Urology. 2003 Jul;62(1):152-7. doi: 10.1016/s0090-4295(03)00137-7.